 A phase I study of azacitidine with Cepleneinterleukin-2 will first evaluate the safety and tolerability of this regimen in patients with higher risk myelodysplastic syndromes MDS who achieved a hematological response after 6 cycles of azacitidine. After approval by an independent Data Safety Monitoring Board DSMB, the phase I study will be followed by an open label randomized phase II study designed to characterize the efficacy, safety, and tolerability of the addition of Cepleneinterleukin-2 to azacytidine in patients with higher risk myelodysplastic syndrome MDS who achieved a hematological response after 6 cycles of azacitidine. 